MESA LABORATORIES INC /CO/ Business Summary

Mesa Laboratories Inc. (MLAB) operates a diversified life sciences tools business model, generating revenue through the sale of precision instruments, high-margin recurring consumables, and specialized laboratory services. The company’s operations are structured into four primary segments: Sterilization and Disinfection Control (SDC), which provides biological and chemical indicators; Biopharmaceutical Development (BPD), focusing on automated protein analysis and peptide synthesis; Calibration Solutions (CS), offering gas flow and environmental monitoring tools; and Clinical Genomics (CG), which delivers genetic analysis systems like the MassARRAY. Mesa Labs serves highly regulated sectors including pharmaceuticals, healthcare, and medical device manufacturing, positioning itself as a critical quality control partner. It competes directly with industry giants such as 3M, STERIS, Getinge, and Thermo Fisher Scientific, maintaining a competitive edge through its niche focus on sterilization validation and process monitoring in regulated environments. Founded in 1982 by Luke R. Schmieder, Mesa Laboratories is currently led by a management team with deep pedigree in the life sciences and industrial technology sectors. President and CEO Gary Owens, who joined in 2017, previously held executive roles at Danaher Corporation, including leadership within Beckman Coulter Life Sciences. He is supported by CFO John V. Sakys, who has overseen the company’s financial strategy since 2012, and Brian Archbold, SVP of Continuous Improvement, another Danaher and Thermo Fisher veteran. The company’s governance is bolstered by a board of directors that includes Chairman and former CEO John J. Sullivan, as well as industry experts like Shannon M. Hall (formerly of Bio-Rad) and Shiraz S. Ladiwala (formerly of Thermo Fisher). Mesa Labs maintains a strong institutional investor base, with approximately 95% of shares held by entities such as Eagle Asset Management and Dimensional Fund Advisors.